An early-stage life science platform with focus in Americas and Europe

Research and technology driven approach disrupting old practices and paving way for new realities

ABOUT US

The AGP Difference

Differentiated Strategy

which gives exposure via both funds (50%) and directs (50%)

Disrupting Old Practices

by using a Techonology and Data-driven approach

Investment Team

with a strong pedigree in both Life Sciences as well as Investments

Global Footprint

with a presence in San Francisco, Boston, NewYork, London, Riyadh, Dubai, Mumbai and Taipei.

Why Early-Stage Life Science?

Sector at an infection point and poised for major disruption

Biggest wealth creation opportunity during our lifetime


Last few decades were all about technology, next few decades would be about life sciences

Strong government support with non-dilutive grants

Early stage gets less than 5% of the total private funding for this sector


Robust biopharma exit market with average years to exit of 3.5 years for M&A transactions

Sector at an infection point and poised for major disruption

Biggest wealth creation opportunity during our lifetime


Last few decades were all about technology, next few decades would be about life sciences

Strong government support with non-dilutive grants

Early stage gets less than 5% of the total private funding for this sector


Robust biopharma exit market with average years to exit of 3.5 years for M&A transactions

At Inflection Point



Old Practices

Slow, Reactive, Biased

  • Little real-time data


  • Does not support prevention


  • Not patient centric experience


  • Mass generalization


  • Complex regulations



Future Practices

Predictive, Preventive, Real-time

  • Real-time data


  • Predictive and preventive approach


  • Personalized & customization


  • AI, machine learning, cloud based


  • Digitalization of clinical